Tuan Dinh Le1, Nga Thi Phi Nguyen2,3, Binh Nhu Do4, Son Tien Nguyen2,3, Hoa Thi Thanh Tran5, Lan Thi Ho Nguyen5, Hoang Huy Duong1, Ha Manh Nguyen5. 1. Department of Internal Medicine, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam. 2. Department of Endocrinology, Military Hospital 103, Ha Noi, Vietnam. 3. Department of Rheumatology and Endocrinology, Vietnam Military Medical University, Ha Noi, Vietnam. 4. Division of Military Science, Military Hospital 103, Ha Noi, Vietnam. 5. The National Endocrinology Hospital, Ha Noi, Vietnam.
Abstract
INTRODUCTION: To investigate effects of Sitagliptin on the enhancement of beta-cell function, reducing insulin resistance, serum glucagon like peptide-1 (GLP-1) concentrations and blood glucose in patients with type 2 diabetes mellitus (T2D) and suggest one of the underlying mechanisms on beta-cell function and insulin resistance. PATIENTS AND METHODS: This was a cross-sectional and observational study in comparison to the control group. A study population of 44 newly diagnosed patients with T2D treated with Sitagliptin with a dose of 100 mg/day for 3 months was analyzed to compare 52 healthy participants. Indices for beta-cell function, peripheral insulin sensitivity, and insulin resistance were calculated with homeostasis model assessment 2 (HOMA2) calculator and compared. Serum GLP-1 concentrations were analyzed, and regression analysis was conducted to find the correlations between GLP-1 and beta-cell function and insulin resistance. RESULTS: Newly diagnosed patients with T2D witnessed a significant reduction in beta-cell function, serum GLP-1 concentrations at the time of diagnosis. After treatment with Sitagliptin 100 mg/day, they achieved significant improvements in beta-cell function, peripheral insulin sensitivity and insulin resistance. Serum GLP-1 concentrations were increased significantly to those levels in the control group and correlated with peripheral insulin sensitivity and insulin resistance in patients whose beta-cell functions improved. CONCLUSION: Sitagliptin improved beta-cell function, insulin resistance and blood glucose in newly diagnosed patients with T2D. Meanwhile, Sitagliptin ameliorated serum GLP-1 concentrations, which contributed to the enhancement of beta-cell.
INTRODUCTION: To investigate effects of Sitagliptin on the enhancement of beta-cell function, reducing insulin resistance, serum glucagon like peptide-1 (GLP-1) concentrations and blood glucose in patients with type 2 diabetes mellitus (T2D) and suggest one of the underlying mechanisms on beta-cell function and insulin resistance. PATIENTS AND METHODS: This was a cross-sectional and observational study in comparison to the control group. A study population of 44 newly diagnosed patients with T2D treated with Sitagliptin with a dose of 100 mg/day for 3 months was analyzed to compare 52 healthy participants. Indices for beta-cell function, peripheral insulin sensitivity, and insulin resistance were calculated with homeostasis model assessment 2 (HOMA2) calculator and compared. Serum GLP-1 concentrations were analyzed, and regression analysis was conducted to find the correlations between GLP-1 and beta-cell function and insulin resistance. RESULTS: Newly diagnosed patients with T2D witnessed a significant reduction in beta-cell function, serum GLP-1 concentrations at the time of diagnosis. After treatment with Sitagliptin 100 mg/day, they achieved significant improvements in beta-cell function, peripheral insulin sensitivity and insulin resistance. Serum GLP-1 concentrations were increased significantly to those levels in the control group and correlated with peripheral insulin sensitivity and insulin resistance in patients whose beta-cell functions improved. CONCLUSION: Sitagliptin improved beta-cell function, insulin resistance and blood glucose in newly diagnosed patients with T2D. Meanwhile, Sitagliptin ameliorated serum GLP-1 concentrations, which contributed to the enhancement of beta-cell.
Authors: James Mu; John Woods; Yun-Ping Zhou; Ranabir Sinha Roy; Zhihua Li; Emanuel Zycband; Yue Feng; Lan Zhu; Cai Li; Andrew D Howard; David E Moller; Nancy A Thornberry; Bei B Zhang Journal: Diabetes Date: 2006-06 Impact factor: 9.461
Authors: Y Wang; R Perfetti; N H Greig; H W Holloway; K A DeOre; C Montrose-Rafizadeh; D Elahi; J M Egan Journal: J Clin Invest Date: 1997-06-15 Impact factor: 14.808
Authors: Helena W Rodbard; Paul S Jellinger; Jaime A Davidson; Daniel Einhorn; Alan J Garber; George Grunberger; Yehuda Handelsman; Edward S Horton; Harold Lebovitz; Philip Levy; Etie S Moghissi; Stanley S Schwartz Journal: Endocr Pract Date: 2009 Sep-Oct Impact factor: 3.443